|
|
| | pyripyropene A Basic information |
| Product Name: | pyripyropene A | | Synonyms: | pyripyropene A;FO 1289A;2H,11H-Naphtho[2,1-b]pyrano[3,4-e]pyran-11-one, 3,6-bis(acetyloxy)-4-[(acetyloxy)methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-9-(3-pyridinyl)-, (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-;Pyripyropene A, ACAT2 inhibitor | | CAS: | 147444-03-9 | | MF: | C31H37NO10 | | MW: | 583.63 | | EINECS: | | | Product Categories: | | | Mol File: | 147444-03-9.mol |  |
| | pyripyropene A Chemical Properties |
| Melting point | 153-154℃ | | Boiling point | 690.8±55.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C, protect from light, stored under nitrogen | | solubility | DMSO: Soluble; Methanol: Soluble | | pka | 11.72±0.70(Predicted) | | form | White to brown powder. | | color | Pale pink to rusty brown |
| | pyripyropene A Usage And Synthesis |
| Uses | Pyripyropene A exhibits insecticidal properties and a useful compound for developing agrichemicals. | | Definition | ChEBI: A sesquiterpenoid that consists of (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-(acetoxymethyl)-12-hydroxy-4,6a,12b-trimethyl-11-o
o-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diol in which the hydrogens of the 3- and 6-hydroxy functions are substituted by acetyl groups. | | in vivo | Pyripyropene A (10-50 mg/kg per day; p.o; 12 weeks) reduces the levels of plasma cholesterol, very-low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) and hepatic cholesterol content in apolipoprotein E-knockout mice. And Pyripyropene A-treated mice display reduction of atherogenic lesion areas in the aortae and heart[3].
Pyripyropene A inhibits the hepatic e acyl–coenzyme A:cholesterol acyltransferase 2 (ACAT2) activity in vivo[3].
Pyripyropene A displays a half-life (t1/2) of 0.693/λ, where λ represented the terminal slope of the log-linear portion of concentration time profile[4].
| Animal Model: | Male C57BL/6 mice[2] | | Dosage: | 0 mg/kg, 1 mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg | | Administration: | Oral administration; daily; for 12 weeks | | Result: | Reduced atherogenic lesion areas in the aortae and heart. |
| Animal Model: | 9-week old male ICR mice (pharmacokinetic analysis)[4] | | Dosage: | 5 mg/kg ,10 mg/kg | | Administration: | Oral administration | | Result: | t1/2 = 0.693/λ |
| | storage | +4°C |
| | pyripyropene A Preparation Products And Raw materials |
| Raw materials | Spiro[1,3-dioxolane-2,1'(2'H)-naphthalen]-6'(5'H)-one, hexahydro-5'-(hydroxymethyl)-5',8'a-dimethyl-, (4'aR,5'R,8'aS)--->Spiro[1,3-dioxolane-2,1'(2'H)-naphthalene]-5'-methanol, octahydro-6'-hydroxy-5',8'a-dimethyl-, (4'aS,5'R,6'S,8'aS)--->Acetic anhydride |
|